Origins of Cystic Fibrosis Airway Disease
Origins of Cystic Fibrosis Airway Disease
批准号:
10470203
负责人:
DAVID A STOLTZ
金额:
$229.33万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-05 至 2024-06-30
关键词:
ATP12A geneAddressAffectAirway DiseaseAnimal ModelAnionsBacteriaBicarbonatesBirthCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDefectDevelopmentDiseaseDisease ProgressionDuct (organ) structureExhibitsFamily suidaeGenetic DiseasesGlandGoalsH(+)-K(+)-Exchanging ATPaseHost DefenseHourHumanImpairmentInfectionInflammationInfrastructureInvestigationKnowledgeLeadLearningLifeLinkLiquid substanceLungLung diseasesMediatingMethodsMorbidity - disease rateMucociliary ClearanceMucous body substanceNewborn InfantPathogenesisPlayPropertyProton PumpProton-Translocating ATPasesProtonsPulmonary Cystic FibrosisRegulator GenesResearchResearch PersonnelRespiratory FailureRespiratory Tract InfectionsRoleSerumServicesSiteSurfaceTechniquesVirus Diseasesairway epitheliumairway obstructionairway surface liquidantimicrobialcystic fibrosis airwaydefined contributiondisease phenotypeearly cystic fibrosisgene discoveryinjured airwayinnovationinsightmortalitynovel therapeutic interventionnovel therapeuticsporcine modelpreventprogramsrecurrent infectionrespiratorysuccessvacuolar H+-ATPase
中文摘要
发现CFTR基因28年后,囊性纤维化(CF)气道的原因
疾病仍然存在争议,我们仍然缺乏许多关键问题的答案,我们的治疗方法是
CF仍然是一种限制生命的疾病,而且往往是致命的疾病。进步的主要障碍
缺乏具有与患有CF的人类相似的肺病表型的CF动物模型。我们
培育出CFTR基因有针对性改变的猪。CF猪会自发地发展出
CF肺病的特征,包括气道感染、炎症、气道壁重塑、粘液
积聚和气道阻塞。在出生后的几个小时内,CF猪无法根除细菌,
与野生型猪一样。至少两种宿主防御缺陷,气道抗菌活性降低
表面液体(ASL)和受损的粘膜纤毛转运(MCT)起作用。两者都是由
异常酸性的气道液体。在这个项目中,三位非常有成就的研究人员将使用CF猪
来回答有关CF肺病的基本问题。这三个项目将共同探索
CFTR功能丧失影响:a)粘膜下腺体功能、粘液性质和MCT; B)ASL
通过ATP 12 A的pH和质子分泌;以及c)小气道功能,CF疾病的可能部位
发病机制项目负责人及其团队在协作CF方面有着出色的记录
研究,在这里,他们把注意力集中在一个共同的目标上。他们极具创造性的研究
由提供创新基础设施和服务的五个核心提供支持。通过进一步教育CF
它将加速发现这种致命疾病的新疗法。
英文摘要
Twenty-eight years after the discovery of the CFTR gene, the causes of cystic fibrosis (CF) airway
disease remain controversial, we still lack answers to many critical questions, our therapies are
inadequate, and CF remains a life limiting and too often lethal disease. A major impediment to progress
has been lack of CF animal models with a lung disease phenotype resembling humans with CF. We
developed pigs with targeted alterations of the CFTR gene. CF pigs spontaneously develop the hallmark
features of CF lung disease, including airway infection, inflammation, airway wall remodeling, mucus
accumulation, and airway obstruction. Within hours of birth, CF pigs fail to eradicate bacteria as
effectively as wild-type pigs. At least two host defense defects, reduced antimicrobial activity in airway
surface liquid (ASL) and impaired mucociliary transport (MCT) contribute. Both were caused by
abnormally acidic airway liquid. In this Program three highly accomplished investigators will use CF pigs
to answer fundamental questions about CF lung disease. Together, the three projects will discover how
loss of CFTR function affects: a) submucosal gland function, the properties of mucus, and MCT; b) ASL
pH and proton secretion via ATP12A; and, c) small airways function, a likely site of CF disease
pathogenesis. The Project Leaders and their teams have an outstanding track record of collaborative CF
research, and here they sharpen their focus to a common goal. Their highly creative research is
supported by five cores that provide innovative infrastructure and services. By further educating CF
pathogenesis, it will accelerate discovery of novel therapies for this lethal disease.
期刊论文(126)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.jcf.2014.02.004
发表时间:
2014-09
期刊:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
影响因子:
--
作者:
[Reznikov LR, Abou Alaiwa MH, Dohrn CL, Gansemer ND, Diekema DJ, Stoltz DA, Welsh MJ]
通讯作者:
Welsh MJ
Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice.
具有缩短的 R 结构域的囊性纤维化跨膜电导调节剂可挽救 CFTR-/- 小鼠的肠道表型。
DOI:
10.1073/pnas.1019752108
发表时间:
2011
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[Ostedgaard,LyndaS, Meyerholz,DavidK, Vermeer,DanielW, Karp,PhilipH, Schneider,Lindsey, Sigmund,CurtD, Welsh,MichaelJ]
通讯作者:
Welsh,MichaelJ
CFTR-deficient pigs display peripheral nervous system defects at birth.
CFTR 缺陷的猪在出生时表现出周围神经系统缺陷。
DOI:
10.1073/pnas.1222729110
发表时间:
2013
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[Reznikov,LeahR, Dong,Qian, Chen,Jeng-Haur, Moninger,ThomasO, Park,JungMin, Zhang,Yuzhou, Du,Jianyang, Hildebrand,MichaelS, Smith,RichardJH, Randak,ChristophO, Stoltz,DavidA, Welsh,MichaelJ]
通讯作者:
Welsh,MichaelJ
DOI:
10.1016/j.jcf.2022.08.019
发表时间:
2023-03
期刊:
JOURNAL OF CYSTIC FIBROSIS
影响因子:
5.2
作者:
[Ehre, Camille, Hansson, Gunnar C., Thornton, David J., Ostedgaard, Lynda S.]
通讯作者:
Ostedgaard, Lynda S.
DOI:
10.1016/j.vetimm.2008.10.321
发表时间:
2009-03-15
期刊:
Veterinary immunology and immunopathology
影响因子:
1.8
作者:
[Butler JE, Lager KM, Splichal I, Francis D, Kacskovics I, Sinkora M, Wertz N, Sun J, Zhao Y, Brown WR, DeWald R, Dierks S, Muyldermans S, Lunney JK, McCray PB, Rogers CS, Welsh MJ, Navarro P, Klobasa F, Habe F, Ramsoondar J]
通讯作者:
Ramsoondar J
共 53 条
Climate Change and Lung Health Training Program
-
批准号:10556149
-
项目类别:
-
资助金额:$28.85万
-
财政年份:2023
-
负责人:DAVID A STOLTZ
-
依托单位:
Testing the Contributions of Airway Submucosal Glands and Surface Epithelia to Lung Health
-
批准号:10597111
-
项目类别:
-
资助金额:$62.95万
-
财政年份:2022
-
负责人:DAVID A STOLTZ
-
依托单位:
Animal Models Core
-
批准号:10677590
-
项目类别:
-
资助金额:$59.97万
-
财政年份:2020
-
负责人:DAVID A STOLTZ
-
依托单位:
Animal Models Core
-
批准号:10024664
-
项目类别:
-
资助金额:$61.06万
-
财政年份:2020
-
负责人:DAVID A STOLTZ
-
依托单位:
Animal Models Core
-
批准号:10248526
-
项目类别:
-
资助金额:$60.83万
-
财政年份:2020
-
负责人:DAVID A STOLTZ
-
依托单位:
Animal Models Core
-
批准号:10470334
-
项目类别:
-
资助金额:$59.97万
-
财政年份:2020
-
负责人:DAVID A STOLTZ
-
依托单位:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
-
批准号:10155587
-
项目类别:
-
资助金额:$105.36万
-
财政年份:2017
-
负责人:DAVID A STOLTZ
-
依托单位:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
-
批准号:9289053
-
项目类别:
-
资助金额:$107.03万
-
财政年份:2017
-
负责人:DAVID A STOLTZ
-
依托单位:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
-
批准号:9918957
-
项目类别:
-
资助金额:$105.46万
-
财政年份:2017
-
负责人:DAVID A STOLTZ
-
依托单位:
Airway Goblet Cells: Friend or Foe?
-
批准号:8355114
-
项目类别:
-
资助金额:$226.5万
-
财政年份:2012
-
负责人:DAVID A STOLTZ
-
依托单位:
Paraoxonase-2 S311C Polymorphism Alters Glycosylation and Lactonase Activity
-
批准号:8110743
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2010
-
负责人:DAVID A STOLTZ
-
依托单位:
Paraoxonase-2 S311C Polymorphism Alters Glycosylation and Lactonase Activity
-
批准号:7919812
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2009
-
负责人:DAVID A STOLTZ
-
依托单位:
Project 1: Mucociliary Transport in Cystic Fibrosis Lung Disease
-
批准号:10470210
-
项目类别:
-
资助金额:$37.18万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Core A: Animals Models-Stoltz
-
批准号:10470206
-
项目类别:
-
资助金额:$71.22万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Porcine PPG Administration Core
-
批准号:10470205
-
项目类别:
-
资助金额:$6.23万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Origins of Cystic Fibrosis Airway Disease
-
批准号:10226930
-
项目类别:
-
资助金额:$229.38万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Core A: Animals Models-Stoltz
-
批准号:10226932
-
项目类别:
-
资助金额:$71.27万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Porcine PPG Administration Core
-
批准号:10226931
-
项目类别:
-
资助金额:$6.23万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Project 1: Mucociliary Transport in Cystic Fibrosis Lung Disease
-
批准号:10226937
-
项目类别:
-
资助金额:$37.18万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Paraoxonase-2 S311C Polymorphism Alters Glycosylation and Lactonase Activity
-
批准号:7994211
-
项目类别:
-
资助金额:$12.63万
-
财政年份:2007
-
负责人:DAVID A STOLTZ
-
依托单位:
海外基金